Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
BMC Anesthesiol. 2022 Jul 29;22(1):240. doi: 10.1186/s12871-022-01786-3.
Hypotension that is resistant to phenylephrine is a complication that occurs in anesthetized patients treated with angiotensin converting enzyme (ACE) inhibitors. We tested the hypothesis that Ang 1-7 and the endothelial Mas receptor contribute to vasodilation produced by propofol in the presence of captopril.
The internal diameters of human adipose resistance arterioles were measured before and after administration of phenylephrine (10 to 10 M) in the presence and absence of propofol (10 M; added 10 min before the phenylephrine) or the Mas receptor antagonist A779 (10 M; added 30 min before phenylephrine) in separate experimental groups. Additional groups of arterioles were incubated for 16 to 20 h with captopril (10 M) or Ang 1-7 (10 M) before experimentation with phenylephrine, propofol, and A779.
Propofol blunted phenylephrine-induced vasoconstriction in normal vessels. Captopril pretreatment alone did not affect vasoconstriction, but the addition of propofol markedly attenuated the vasomotor response to phenylephrine. A779 alone did not affect vasoconstriction in normal vessels, but it restored vasoreactivity in arterioles pretreated with captopril and exposed to propofol. Ang 1-7 reduced the vasoconstriction in response to phenylephrine. Addition of propofol to Ang 1-7-pretreated vessels further depressed phenylephrine-induced vasoconstriction to an equivalent degree as the combination of captopril and propofol, but A779 partially reversed this effect.
Mas receptor activation by Ang 1-7 contributes to phenylephrine-resistant vasodilation in resistance arterioles pretreated with captopril and exposed to propofol. These data suggest an alternative mechanism by which refractory hypotension may occur in anesthetized patients treated with ACE inhibitors.
血管紧张素转换酶(ACE)抑制剂治疗的麻醉患者出现去甲肾上腺素抵抗性低血压是一种并发症。我们检验了这样一个假设,即在卡托普利存在的情况下,血管紧张素 1-7 和内皮 Mas 受体有助于丙泊酚引起的血管扩张。
在分别的实验组中,在去甲肾上腺素(10 到 10-7 M)给药前后,测量人脂肪阻力小动脉的内径,这些实验组中存在或不存在丙泊酚(10-6 M;在去甲肾上腺素前 10 分钟添加)或 Mas 受体拮抗剂 A779(10-6 M;在去甲肾上腺素前 30 分钟添加)。在与去甲肾上腺素、丙泊酚和 A779 进行实验之前,将另外的小动脉组孵育 16 到 20 小时,用卡托普利(10-6 M)或血管紧张素 1-7(10-6 M)预处理。
丙泊酚减弱了正常血管中去甲肾上腺素引起的血管收缩。单独的卡托普利预处理本身并不影响血管收缩,但添加丙泊酚可显著减弱对去甲肾上腺素的血管运动反应。A779 单独作用于正常血管不会引起血管收缩,但它恢复了暴露于丙泊酚并经卡托普利预处理的小动脉的血管反应性。血管紧张素 1-7 降低了对去甲肾上腺素的血管收缩。将丙泊酚添加到血管紧张素 1-7 预处理的血管中,可进一步降低与卡托普利和丙泊酚联合使用相同程度的去甲肾上腺素引起的血管收缩,但 A779 部分逆转了这种作用。
在暴露于丙泊酚并经卡托普利预处理的阻力小动脉中,血管紧张素 1-7 对 Mas 受体的激活有助于去甲肾上腺素抵抗性血管扩张。这些数据表明,在接受 ACE 抑制剂治疗的麻醉患者中,可能会出现难治性低血压的另一种机制。